Deregulation of p53/survivin apoptotic markers correlated to PTEN expression in pterygium neoplastic cells


1Department of Ophthalmology, General Hospital, Kalamata, Greece; 2Department of Immunohistochemistry-Molecular Biology, 401 GAH, Athens, Greece; 3Department of Pathology, Medical School, University of Athens, Athens, Greece; 4Department of Pathology, 417 VA Hospital, Athens, Athens, Greece; 5Department of Ophthalmology, Medical School, University of Ioannina, Ioannina, Greece; 6Department of Maxillofacial Surgery, Medical School, University of Ioannina, Ioannina, Greece

*These authors contributed equally to this study

Summary

**Purpose:** Pterygium is a distinct clinicopathological entity characterized by degenerated and neoplastic-like features. Concerning its rise on normal conjunctiva epithelia, the role of specific gene deregulations including apoptotic/anti-apoptotic factors and significant suppressor genes in signaling transduction pathways is under investigation. In the current study, we co-analyzed p53, survivin and PTEN proteins in pterygia and normal conjunctiva.

**Methods:** Using a liquid-based cytology assay, 50 cell specimens were obtained by a smooth scraping on conjunctiva epithelia and fixed accordingly. Among them, 38 were pterygia and the remaining (n=12) normal epithelia (control group). Immunocytochemistry assays were implemented on the corresponding slides by applying anti-p53, survivin, and PTEN antibodies. Digital image analysis was performed for evaluating objectively the corresponding immunostaining intensity levels.

**Results:** The majority of the examined pterygia cases overexpressed the markers p53:22/38-57.9%, survivin:30/38-78.9%, and PTEN:25/38-65.7%. Interestingly, overall p53/PTEN co-expression was found to be statistically significant (p=0.022).

**Conclusions:** Survivin overexpression leads to an increased anti-apoptotic activity playing a central molecular role in the pathogenesis and progression of pterygia. Furthermore, although p53 expression is observed in these lesions, its impact seems to be low compared to survivin's influence on them. Additionally, the role of PTEN in the process is potentially significant providing a suppressor balance to the p53/survivin complex.

**Key words:** apoptosis, cytology, genes, image analysis, pterygia

Introduction

Pterygium represents a frequent and partially unexplored epithelial lesion affecting the conjunctiva [1]. High levels of ultraviolet (UV) radiation exposure seem to be the main pathogenetic factor. Increased oxidative DNA damage due to aberrant UV influence acts as a central mechanism leading
to an epithelial micro-environment transformation [2]. Concerning the morphological changes that modify normal conjunctiva epithelia, pterygia demonstrate an abnormal, mainly triangular shape growth pattern, affecting the cornea. Although the lesion is generally considered to be benign, a grade of progressive dysplasia combined with inflammation and sometimes a tissue invasive pattern has been reported. In fact, categorization of pterygium as lesion is difficult because of its nature and progression as a disease. Degeneration of the normal conjunctiva and localized neoplastic entity should be two different but closely related aspects of the same lesion [3].

Molecular analyses regarding pterygia have shown that deregulation of critical genes - implicated in cell proliferation, apoptosis and also signal transduction to the nucleus - are potentially involved in the progression of the lesion. Among them, survivin and p53 are main regulators of cell and tissue homeostasis due to their influence in the apoptotic pathways [4]. Survivin (gene locus: 17q25) is a member of the inhibitor of apoptosis (IAP) gene family which counteracts apoptosis by inhibiting the activity of initiators and effectors caspases. Survivin associates with the microtubules in the mitotic spindle and antagonizes mitochondrial-dependent apoptosis [5]. Survivin is also involved in cell division. In fact, survivin demonstrates a high expression at G2/M phase and declines rapidly in G1 phase of the cell cycle. On the other hand, p53 - a nuclear phosphoprotein - is a central genome gate-keeper (gene locus:17p13). It acts as a transcription factor for crucial genes, inhibiting abnormal DNA replication and regulating apoptosis. Mutant p53 due to somatic gene mutations leads to a nuclear-based protein over-expression pattern transforming its role from a suppressor to an oncogene [6]. In conjunction to the previous referred genes, PTEN (gene locus:10q23.3-phosphatase and tensin homolog deleted in chromosome 10) is a tumor suppressor gene that is deleted, mutated or epigenetically hypermethylated in a variety of human malignancies. PTEN acts as a negative regulator of this specific pathway [7]. Normal expression of PTEN induces growth suppression by promoting cell cycle arrest. It is also correlated with decreased levels and nuclear localization of cyclin D1 regulated by AKT that positively induces cell cycle [8]. In the current research study, we intended to explore the impact of the combined p53, PTEN, and survivin protein expression in pterygia epithelia.

**Methods**

**Cell substrates**

For the purposes of our study, 50 cell samples were obtained by applying a smooth scraping on the corresponding conjunctiva epithelia. The mean patient age

![Figure 1. Immunocytochemistry analysis for the markers A: p53 expression (nuclear staining pattern). B: PTEN expression (cytoplasmic mainly and nuclear staining pattern). C: survivin (nuclear predominantly and cytoplasmic staining pattern). Second row: negative expression, original magnification 400×.](image-url)
was 63 years. All of the patients were informed and consented to the use of these cell samples for research purposes, according to World Medical Association Declaration of Helsinki guidelines. Using a liquid-based cytology assay (LiquiPrep, LGMI, Inc, Melbourne, FL, USA) all of the cell specimens were collected and fixed accordingly. Among them, 38 were obtained from pterygia and the remaining 12 from normal epithelia (control group). The final fixed slides were used for immunocytochemistry (ICC) analysis.

**Immunocytochemistry assay**

ICC for survivin, p53 and PTEN antigens was carried out on liquid-based fixed slides described above. Anti-survivin mouse monoclonal antibody (clone 12C4, Dako NA Inc, CA, USA; dilution at 1:100), anti-p53 mouse monoclonal antibody (clone DO-7, Dako NA Inc, CA, USA; dilution at 1:40), anti-PTEN mouse monoclonal antibody (clone 6H2.1, Dako NA Inc, CA, USA; dilution at 1:100) were applied properly according to the EN Vision + (Dako NA Inc, CA, USA) assay using an automated staining system (I 6000, Biogenex, USA). This specific assay is based on a soluble, dextran-polymer system preventing an endogenous biotin reaction and increasing the quality of the stained slides. Briefly, the sections were incubated with the primary antibody for 50 min at room temperature and then incubated with the polymer for 30 min. The antigen-antibody reaction was visualized using 3, 3- diaminobenzidine tetrahydrochloride (DAB) as a chromogen substrate. Finally, the slides were slightly counterstained with hematoxylin for 30 s, dehydrated and mounted. According to the manufacturer’s guidelines, breast cancer tissue samples previously reported to express these markers were used as positive controls for them. Nuclear staining pattern was acceptable for p53 expression, whereas cytoplasmic mainly and nuclear pattern were both acceptable for PTEN expression. Concerning survivin, nuclear predominantly and cytoplasmic immunostaining was considered as acceptable expression (Figure 1A-C). Digital image analysis was performed to objectively evaluate the corresponding immunostaining intensity levels.

**Digital image analysis (DIA) assay**

In order to evaluate p53, PTEN and survivin ICC results, in an accurate objective and fast way, DIA was performed by applying a semi-automated system with the following hardware features: Intel Pentium Dual-Core, Digital Camera Sony Cyber-shot (5Mp digital analysis), Microscope Olympus CX-31 and the corresponding software: Windows XP platform/NIS–elements image analysis software, Nikon, Jp 2009. A digitized database was constructed including all the snapshots of the immunostained liquid cytology-based slides. A macro was implemented for evaluating those slides. Measurements of staining intensity values were performed in 5 optical fields per case and at original magnification of 400x. All measurements were performed inside a stable active window focused on isolated or clusters of detected epithelial mainly and stromal cells (Figure 2).

**Figure 2.** Computerized image analysis of a case of survivin protein expression objective evaluation. Reddish areas demonstrate different expression values (range: 0-255 grey scale immunostaining intensity levels).
All numerical data were filed in Microsoft Excel sheets for statistical analysis. Staining intensity levels were obtained in a range of 256 continuous values, including the RGB protocol in grey scale as follows: 0: absolute black (ultimate overexpression), 255: absolute white (loss of expression). Control group values (normal epithelia vs pterygia) were obtained also by the corresponding measurements.

**Statistics**

Associations between PTEN, p53, and survivin protein expression levels and pterygia clinicopathological parameters were performed by applying chi-square and Fischer’s tests (SPSS v 20.0 statistical software- Inc Chicago IL, USA). Total results regarding the corresponding grouped measurements for the examined markers and also p values are described in Table 1.

**Results**

According to previous referred protein analysis mediated by DIA, all of the examined cases demonstrated PTEN/surviving/p53 expression in different immunostaining levels. The majority of the examined pterygia cases overexpressed the markers (p53: 22/38-57.9%, survivin: 30/38-78.9%, and PTEN: 25/38-65.7%, respectively). Interestingly, overall p53/PTEN co-expression was found to be statistically significant (p=0.022). Overexpression of survivin mainly and of p53 was significantly associated to abnormal conjunctiva epithelia (p=0.019, p=0.03, respectively). No statistical significance was observed regarding the age of the examined patients.

**Discussion**

Based on extensive molecular analyses, tissue stability is mediated by a balance between cellular proliferation and apoptosis [9]. The way that normal conjunctival epithelia transform into pterygium lesion is under investigation. Some studies have shown that the progressive development of the lesion should be a result of an aberrant expression of apoptotic and also anti-apoptotic factors. P53 expression combined with bcl-2 (an inhibitor of apoptosis) and also Bax (a promoter of apoptosis) increased levels have been detected in pterygia [10]. This genetic mechanism is not observed in normal epithelia. In fact, the role of p53 is to prevent the aberrant expression of bcl-2 and to induce the bax protein production. Besides this genetic deregulation, survivin seems to be a crucial molecule in pterygia development. As a member of the apoptosis inhibitors superfamily, suppresses the apoptotic process. Concerning pterygia, elevated gene transcription leads to protein overexpression in them. A study group analyzed the marker at the m-RNA and protein level showing that phosphorylated survivin was detected mainly in the cytoplasm and also in the nucleus [11]. Interestingly, they suggested that the protein could be targeted for the treatment of the lesion by specific siRNA implementation in vitro by mixed keratinocyte and pterygium epithelial cells. Similarly, another study showed that the combined p53 and survivin overexpression was correlated with not only primary development of pterygia but also with their recurrence [12]. According to our protein expression results, survivin mainly and p53 increased immunoreactivity was associated to abnormal conjunctiva epithelia. This observation enhances the role of the molecule in the deregulation of the apoptotic mechanism in these epithelia. Furthermore, the molecule seems to overreact with other proteins including cyclooxygenase-2 (COX-2) and the cyclic

<table>
<thead>
<tr>
<th>Table 1. Total results of the examined markers and also p values</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=50</td>
</tr>
<tr>
<td>p53</td>
</tr>
<tr>
<td>Pterygia (n=38)</td>
</tr>
<tr>
<td>Type</td>
</tr>
<tr>
<td>Flat (n=22)</td>
</tr>
<tr>
<td>Fleshy (n=16)</td>
</tr>
<tr>
<td>Localization</td>
</tr>
<tr>
<td>Central (n=18)</td>
</tr>
<tr>
<td>Peripheral (n=20)</td>
</tr>
<tr>
<td>Control (n=12)</td>
</tr>
<tr>
<td>(normal epithelia)</td>
</tr>
</tbody>
</table>

L: low expression, OE: overexpression, NS: non significant
p53 mean values (pterygia: 126.4, control: 147.9); PTEN mean values (pterygia: 121.6, control: 139.5); Survivin mean values (pterygia: 115.7, control: 141.7). p53 staining intensity levels (range 0-255). p53/PTEN co-expression (p=0.022).
AMP response element-binding protein (CREB) at the basis of pterygia rise [13,14]. Additionally to those interactions, survivin demonstrates an indirect relationship with oxidative DNA damage. According to a relative study, oxidative stress potentially leads to a significant activation of survivin expression promoting development of pterygium [15].

The role of p53 is also under consideration in pterygia neoplastic progression. There are controversial data regarding the expression of the marker. Some studies support the idea that, although abnormal expression is observed in primary pterygial epithelia, there was no connection between them and recurrence of the lesion [16,17]. Based on our immunocytological expression results, overall p53/PTEN co-expression was found to be significantly associated to abnormal conjunctiva epithelia. This observation shows the potential active role of PTEN influence in the development of the lesion. There are no gross and solid data regarding the PTEN expression involvement in the pathogenesis of the pterygium, although it is implicated in critical cellular actions. Embryo-histogenetic analyses have demonstrated that PTEN expression regulates significantly the retinal architecture modifying its functionality, and also its downregulation in injured corneal epithelium induces cell migration and wound healing by promoting PI3K/Akt signaling pathway [18-20]. Additionally, experimental studies in biological species, such as mice and Drosophila, proved that PTEN affects cell size, cell proliferation and apoptosis during their eye development [21]. Concerning pterygia development, PTEN overactivation that significantly suppresses signal transduction to the nucleus could be an indirect mechanism in the apoptotic process. In fact, previous studies analyzing its role in tumor genesis have shown that PTEN-induced downregulation of survivin increased apoptosis in tumor cells, in a reaction reversed by re-expression of recombinant survivin [22,23]. Finally, in our study we implemented a version of exfoliative cytology - liquid based scraping - in order to collect the corresponding specimens and apply immunocytochemistry protocols for the analyzed proteins. This is an easy to use, reliable technique, which has been almost recently performed in similar studies for detecting conjunctival lesions, such as ocular surface squamous neoplasms of the eye [24].

In conclusion, our experimental findings suggest that survivin's overexpression leads to an increased anti-apoptotic activity, playing a central molecular role in the pathogenesis and progression of pterygia. Furthermore, p53 expression is also observed in these lesions, but its impact seems to be low compared to survivin's influence on them. Also, the role of PTEN in the current process is potentially significant providing a suppressor balance to the p53/survivin complex. Additionally, our data support the current growing belief, that pterygia should be regarded as locally expanding neoplastic lesions. Furthermore, their growth affects the normal function of their surrounding tissues, namely the conjunctiva and the cornea, causing chronic irritation and discomfort and most significantly deterioration of vision. Their current surgical treatment carries a low success rate and the use of specific antineoplastic agents may prove the best approach to their treatment.

Conflict of interests

The authors declare no conflict of interests.

References